Lantern Pharma Inc. Debt Securities, Unrealized Gain (Loss)
Lantern Pharma Inc. (LTRN) reported Debt Securities, Unrealized Gain (Loss) of $108.49 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesUnrealizedGainLoss · last filed 2024-11-07
- Lantern Pharma Inc. debt securities, unrealized gain (loss) for the quarter ending 2024-09-30 was $38.06K, a 53.02% decline year-over-year.
- Lantern Pharma Inc. debt securities, unrealized gain (loss) for the quarter ending 2024-06-30 was $26.48K, a 21.56% decline year-over-year.
- Lantern Pharma Inc. debt securities, unrealized gain (loss) for the quarter ending 2024-03-31 was $43.95K, a 13.45% decline year-over-year.
- Lantern Pharma Inc. debt securities, unrealized gain (loss) for the quarter ending 2023-12-31 was -$447.79K, a 555.10% decline year-over-year.
- Lantern Pharma Inc. debt securities, unrealized gain (loss) for fiscal 2023 was -$282.25K.
- Lantern Pharma Inc. debt securities, unrealized gain (loss) for fiscal 2022 was -$296.45K.
- Lantern Pharma Inc. debt securities, unrealized gain (loss) for fiscal 2021 was -$92.87K.
| Period end | Debt Securities, Unrealized Gain (Loss) 3 month | Debt Securities, Unrealized Gain (Loss) 3 month as first filed | Debt Securities, Unrealized Gain (Loss) 6 month | Debt Securities, Unrealized Gain (Loss) 9 month | Debt Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2024-09-30 | $38.06K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $64.54K derived: sum of 2 quarters · filed 2024-11-07 | $108.49K 10-Q · filed 2024-11-07 | -$339.31K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-06-30 | $26.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $70.43K 10-Q · filed 2024-08-08 | -$377.36K derived: sum of 3 quarters · filed 2024-08-08 | -$296.36K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2024-03-31 | $43.95K 10-Q · filed 2024-05-09 | -$403.85K derived: sum of 2 quarters · filed 2024-05-09 | -$322.84K derived: sum of 3 quarters · filed 2024-11-07 | -$289.08K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-12-31 | -$447.79K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$366.79K derived: sum of 2 quarters · filed 2024-11-07 | -$333.02K derived: sum of 3 quarters · filed 2024-11-07 | -$282.25K 10-K · filed 2024-03-18 | |
| 2023-09-30 | $81.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $114.77K derived: sum of 2 quarters · filed 2024-11-07 | $165.54K 10-Q · filed 2024-11-07 | $263.94K derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $33.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $84.54K 10-Q · filed 2024-08-08 | $182.93K derived: sum of 3 quarters · filed 2024-08-08 | $64.36K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $50.77K 10-Q · filed 2024-05-09 | $149.17K derived: sum of 2 quarters · filed 2024-05-09 | $30.60K derived: sum of 3 quarters · filed 2024-05-09 | -$33.19K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $98.39K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$20.18K derived: sum of 2 quarters · filed 2024-03-18 | -$83.96K derived: sum of 3 quarters · filed 2024-03-18 | -$296.45K 10-K · filed 2024-03-18 | |
| 2022-09-30 | -$118.57K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$182.35K derived: sum of 2 quarters · filed 2023-11-08 | -$394.84K 10-Q · filed 2023-11-08 | -$385.03K derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | -$63.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$276.27K 10-Q · filed 2023-08-09 | -$266.45K derived: sum of 3 quarters · filed 2023-08-09 | -$321.58K derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$212.49K 10-Q · filed 2023-05-09 | $212.49K 10-Q · filed 2022-05-03 | -$202.67K derived: sum of 2 quarters · filed 2023-05-09 | -$257.80K derived: sum of 3 quarters · filed 2023-05-09 | |
| 2021-12-31 | $9.82K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | -$45.31K derived: sum of 2 quarters · filed 2023-03-20 | -$92.87K 10-K · filed 2023-03-20 | ||
| 2021-09-30 | -$55.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$102.69K 10-Q · filed 2022-11-07 | |||
| 2021-06-30 | -$47.56K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |